{
    "clinical_study": {
        "@rank": "31832", 
        "arm_group": {
            "arm_group_label": "Repository corticotropin injection", 
            "arm_group_type": "Experimental", 
            "description": "Repository corticotropin injection, 80 United States Pharmacopeia (USP) Units per mL, dosed as 1 mL (80 Units) subcutaneous injection every 72 hours for 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "It is hypothesized that repository corticotropin injection in combination with other\n      biologic agents will be able to provide relief of both rheumatoid arthritis and acute\n      exacerbations of rheumatoid arthritis for patients with disease that had inadequately\n      responded to biologics previously."
        }, 
        "brief_title": "Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Although there are many types of treatment for rheumatoid arthritis (RA) currently\n      available, some patients have disease that is refractory to treatment and cannot achieve\n      remission. The objective of this study is to assess the efficacy and safety of subcutaneous\n      injections of repository corticotropin as an adjunct therapy in patients with active RA who\n      have had an inadequate response to at least two biologic agents as well as a third agent\n      they are currently receiving."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Rheumatoid arthritis of at least 2 years duration\n\n          -  On at least third biologic with a different mechanism of action for at least 12 weeks\n\n          -  Active disease as defined by at least 6 tender and 6 swollen joints\n\n          -  Erythrocyte sedimentation rate (ESR) at least 28 mm/hr or C-reactive protein (CRP) at\n             least 1.2 times the upper limit of normal\n\n          -  Stable dose of disease modifying anti-rheumatic drug (DMARD) and prednisone for at\n             least 4 weeks\n\n        Exclusion Criteria:\n\n          -  Prior treatment with Acthar Gel\n\n          -  History of intolerance or allergy to glucocorticoids\n\n          -  Unstable diabetes\n\n          -  Active infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01966718", 
            "org_study_id": "ATC 005"
        }, 
        "intervention": {
            "arm_group_label": "Repository corticotropin injection", 
            "description": "An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances", 
            "intervention_name": "Repository corticotropin injection", 
            "intervention_type": "Drug", 
            "other_name": "H. P. Acthar Gel"
        }, 
        "intervention_browse": {
            "mesh_term": "Adrenocorticotropic Hormone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rheumatoid arthritis", 
            "Joint pain", 
            "Repository corticotropin injection"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Frederick", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21702"
                }, 
                "name": "Arthritis Treatment Center"
            }, 
            "investigator": [
                {
                    "last_name": "Nathan Wei, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Theresa Gillis, PA-C", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action", 
        "overall_contact": {
            "email": "mgrimm@arthritistreatmentcenter.com", 
            "last_name": "Michelle Grimm", 
            "phone": "301-624-1164"
        }, 
        "overall_contact_backup": {
            "email": "tgillis@arthritistreatmentcenter.com", 
            "last_name": "Theresa Gillis, PA-C, CRC", 
            "phone": "301-624-1168"
        }, 
        "overall_official": {
            "affiliation": "Nathan Wei, MD dba Arthritis Treatment Center, Frederick, MD 21702 USA", 
            "last_name": "Nathan Wei, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A formal count of 68 joints will be conducted to assess for tenderness and/or swelling at each study visit. Changes from baseline to final study visit at week 16 will be evaluated.", 
                "measure": "Change from baseline in the Ritchey-Camp Articular Index", 
                "safety_issue": "No", 
                "time_frame": "From baseline to week 16, measured at 2-6 week intervals"
            }, 
            {
                "description": "Subjects will be asked to complete the 20-item Health Assessment Questionnaire at each study visit. Changes from baseline to final study visit at week 16 will be evaluated.", 
                "measure": "Change from baseline in the 20-item Health Assessment Questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "From baseline to week 16, measured in 2-6 week intervals"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01966718"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Arthritis Treatment Center, Maryland", 
            "investigator_full_name": "Nathan Wei, MD, FACP, FACR:", 
            "investigator_title": "Nathan Wei, MD, FACP, FACR", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "ESR will be obtained as part of the lab work during each study visit. Changes from baseline to the final study visit at week 16 will be evaluated.", 
                "measure": "Change from baseline in the erythrocyte sedimentation rate (ESR)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to week 16, measured at 2-6 week intervals"
            }, 
            {
                "description": "CRP level will be obtained as part of the lab work during each study visit. Changes from baseline to the final study visit at week 16 will be evaluated.", 
                "measure": "Change from baseline in the C-Reactive protein (CRP) level", 
                "safety_issue": "No", 
                "time_frame": "From baseline to week 16, measured in 2-6 week intervals"
            }
        ], 
        "source": "Arthritis Treatment Center, Maryland", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Arthritis Treatment Center, Maryland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}